Santhera Regains U.S., Canadian Rights to Fipamezole in 2011

Oct. 25 (Bloomberg) -- Santhera Pharmaceuticals Holding will regain U.S. and Canadian rights to the fipamezole medicine from Biovail Laboratories as of January 2011, the company said in a statement today.

Link to Statement:{NSN LATXZ93PWT1C <GO>}

Link to Company News:{SANN SW <Equity> CN <GO>}

To contact the editor responsible for this story: Carey Sargent at csargent3@bloomberg.net